Research Associate Assistant

JEAN ZHANG

Acton, MA *************@*****.*** 978-***-****

Scientific capabilities

scientist with many years of comprehensive experience in biotechnology innovations and transformation, precision medicine development in diverse disease areas. Expert in rare disease such as cancer and inflammation disease, Skilled communicator in able to build collaborative relationships with cross-functional peers, engage project and stakeholders, and motivate team success in fast-paced environments. Analytical and organized as well as highly adaptable, proactive, pragmatic in solving complex problems.

TECHNICAL PROFICIENCIES

Cell biology, molecular biology, biochemistry, high-through put assays, bio-platform matrix leverage and integration, small therapeutical molecule discovery. Extensive immuno-oncology assay.

Orphan project for innovative healthcare project initiation. G protein coupled receptor signal pathway, GPCROMICs.

Digital Biopharma R&D platform and pipeline leverage and integration, project collaboration and cooperation.

Micro-physiological tools MPT and micro-physiological system MPS.

Biomarker’s discovery and real-world data initiation and interactions. Clinical and preclinical biomarkers matrix initiation and integrations.

Disease models, digitized bio-assays, single cell. technology, CRISPR Genome editing, synthetic biology. RNAi/shRNA Interference, Nano particles engineering.

EXPERIENCE

Scientific adviser & consultant

Flowcell (partnership)

2020 to current

•translational medicine with Al & bio-computation based digital infrastructure and collaboration and partnership.

•Globe online scientific and business communication and innovation model initiation

•Initiate globe building digital matrix and infrastructure establishment.

•Investigation & development of worldwide partnership for precision medicine in Orphan disease treatment.

•Leadership role in Flowcell business and scientific partnership initiation and expansion, Innovation of cost-effective marketing strategy with scientific writing, leadership & capability coaching in building Flowcell’s streamlined MPT/MPS based bio-computation infrastructure.

Scientific consultant

Career transition and development 2018 to 2020

Biotechnology innovation for life science and healthcare industry R&D transformation

•Globe Anti-COVID covid pandemic efforts, natural and immune medicine receptol, Chinese herb medicine in prevention and treatment of corona virus.

•Globe biopharma R&D platform innovation and integration.

•Investigate microfluidic technology and Stem cell technology for digital biopharma R&D

•Initiate social media for globe bio-science and business communication innovation.

•Consultation and leadership in digital platform for precision medicine development.

GLASKOSMITHKLINE (GSK) - Cambridge, MA

Research Investigator, Pharma Research and Development 2017 to 2018

•proof-of-concept study, develop platforms & execute several projects for small molecule discovery in alignment with immuno-inflammation target discovery.

•Initiated dynamic scientific communication for newly expanded R&D satellite; designed and conducted a site-wide event to enhance a productive multi-cultural working environment.

•Implemented multi-modality methods and infrastructure in alignment with fast-paced translational medicine discovery focused on immuno-inflammation and oncology.

Research Investigator 2017

Platform Technology & Science

•Designed and launched key research strategies and experiments to explore development of encoded DNA small molecule library on polyethylene beads.

•Developed Affinity-Selection-Mass-Spectrometry (ASMS) capabilities for ELT hit validation.

•Led exploration of ASMS technology advantages for optimal target-based small molecule discovery.

Research Investigator, Emerging Platforms 2015 to 2017

•Orchestrated team investigations into organoids, pluripotent, and induced pluripotent stem cells as potential disease models to support therapeutics discovery.

•Authored proposal for implementation of company-wide smart lab methodology and reagent information systems, standardizing international communication and systems.

•Authored proposal to apply transcriptomic technology for identification of biomarkers correlated with antibody aggregation for therapeutic antibody development.

•Played key role in collaborative investigation of new HIV therapeutics discovery with GSK-Academia.

JEAN ZHANG PAGE TWO Research Investigator

Platform Technology and Science 2011 to 2015

•Utilized CRISPR/Cas9 system to generate double-allele knock out NK cell line to improve early oncology target validation for cancer therapeutics discovery.

•Led investigation of gene evolution platform with emulsion droplet of in vitro transcription and translation system, including design of proof-of-concept selection method.

•Successfully identified, validated, and selected several mutated clones to ensure similar wild-type enzymatic activity.

Senior Scientist 2007 to 2013

Platform Technology and Science

•Owned encoded library technology (ELT) selection, innovation, and improvement including testing and validation of several ideas such as ligand-mediated receptor internalization and high-throughput selection for fast-track targets.

•Designed and implemented novel cell-based ELT selection method for membrane protein targets. Successfully identified multiple candidates with various potencies for GPCR targets.

•Led team in investigation of transferases enzyme for conjugation of small molecules to desired target-specific proteins and application to substrate peptide-tagged fusion proteins.

ADDITIONAL RELEVANT EXPERIENCE

Additional experience as Research Investigator - Preclinical Research Group, Lead Research Associate, and Senior Research Associate of Cloning & Strategic Genetics, Research Associate, & Research Assistant, for Precis Pharmaceutical, Dana Farber Cancer Research Institute, Cereon Genomics, and Yale Medical School.

EDUCATION

Master of Science in Biology, Southern Connecticut State University - New Haven, CT

Diploma of Pharmacy in Zhejian, Zhejian Medical College

PUBLICATION

Machutta, C; Kollmann, C.; Lind, K.; Zhang, J. (2017) “Prioritizing Multiple Therapeutic Targets in Parallel Using

Automated DNA-Encoded Library Screening Nature communication.” 8:16081. doi:10.1038/ncomms16081

Wu, Z.; Graybill, Todd L; Zeng, X.; Platchek, M.; Zhang, J.; Bodmer, Vera Q.; Wisnoski, David D.; Deng, J.; Coppo, Frank T.; Yago, G.; Tamburino, A.; Scavello G.; Franklin, G. Joseph; Mataruse, S.; Bedard, Katie L.; Ding, Y.;

Chai, J.; Summerfield, J.; Centrella, P.A.; Messer, J.A.; Pope, A.J.; Israel, D.I. (2015) “Cell-Based Selection Expands the Utility of DNA-Encoded Small-Molecule Library Technology to Cell Surface Drug Targets: Identification of Novel Antagonists of the NK3 Tachykinin Receptor.” ACS Comb. Sci. 17 (12), pp 722–731

Kimmelman, A.C.; Heze, l A.F.; Aguirre, A.J.; Zheng, H; Paik, J.H; Ying, H.; Chu, G.C.; Zhang, J.; Sahin, E.; Yeo, G.; Ponugoti, A.; Nabioullin, R.; Deroo, S.; Yang, S.; Wang, X.; McGrath, J.P.; Protopopova, M.; Ivanova. E.; Feng, B.; Tsao, M.S.; Redston, M.; Protopopov, A.; Xiao, Y.; Futreal, P.A.; Hahn, W.C.; Klimstra, D.S.; Chin, L.; DePinho, R.A. (2008) “Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer.” Proc Natl Acad Sci U S A. Dec 9;105(49):19372-7

Stegh, A.H.; Kim, H.; Bachoo, R.M.; Forloney, K.L.; Zhang, J.; Schulze, H.; Park, K.; Hannon, G.J.; Yuan, J.; Louis,

D.N.; DePinho, R.A.; Chin, L. (2007) Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma.

Genes & Dev. 21: 98 – 111. doi:10.1101/gad.1480007

JEAN ZHANG 978-***-**** PAGE THREE

Aguirre, A.J.; Brennan, C.; Bailey, G.; Sinha, R.; Feng, B.; Leo, C.; Zhang, Y.; Zhang, J.; Gans, J.D.; Bardeesy, N.; Cauwels, C.; Cordon-Cardo, C.; Redston, M.S.; DePinho, R.A.; Chin, L. (2005) High-resolution characterization of the pancreatic adenocarcinoma genome. PNAS. 9067-9072

Ma, J.; Xu, J.; Madaio, M.P.; Peng, Q.; Zhang, J.; Grewal, I.S.; Flavell, R.A.; Craft, J. (1996) Autoimmune lpr/lpr mice deficient in CD40 ligand: spontaneous IG class switching with dichotomy of autoantibody responses. Immunol. Jul1. 157(1), 417-426

Yao, X.; Segal, A.S.; Welling, P.; Zhang, J.; McNicholas, C.M.; Engel, D.; Boulpaep, E.L.; Desir, G.V. (1995) Primary structure and functional expression of a cGMP-gated potassium channel. PNAS. Dec 5. 92(25), 11711-5.

HONORS AND AWARDS

Meeting Award: 2nd Posting Place, 7TM Conference, 2009

Development & validation of ELT selection methods for cell surface targets: application to lipid GPCR receptors

Silver Award, GSK,2018

“Your hard work and dedication… helped push the Tyk2 program to Key decision point.

Excellent Science Award, GSK, 2009

Development of cell-based ELT selection method for high potency antagonist identification for S1P1 using BACMam expression system

Gold Award, GSK, 2008

Development of cell-based ELT selection method for membrane protein target

Bronze Award, GSK, 2007

Progress in development of ELT method for GPCR target screen

Quick Recognition Award for Outstanding Performance, Cereon Genomics, 2000 Development of allele-specific oligo (ASO) hybridization assay.

Contact this candidate